Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Post-Trial Drug Access

Drugs

Locations

Clinical Specialty

81-100 of 847 trials

Nipocalimab for Pregnancies at Risk of Severe Hemolytic Disease

We are studying whether Nipocalimab can help reduce the risk of fetal anemia in pregnant individuals at risk for severe hemolytic disease of the fetus and newborn. This trial compares the treatment to a placebo to assess its effectiveness.

Hemolytic Disease of the Fetus and Newborn>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGynecology and ObstetricsInfectious Diseases

Solid Tumors: SKB264 with Pembrolizumab

We are investigating whether the combination of SKB264 and pembrolizumab is safe and effective for people with selected solid tumors. This study will also explore how the body handles the new drug and its effects on the immune system.

Ovarian CancerCervical CancerUrothelial Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug Access Investigational Medicines Cost ReimbursementOncology

Relapsing Multiple Sclerosis: Rituximab vs. Ocrelizumab

We are studying whether rituximab is as effective as ocrelizumab for treating relapsing MS. This trial is for patients who are starting anti-CD20 therapy.

Multiple Sclerosis>2 yearsMonitoring phase (IV)Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementInternal MedicineNeurology

Advanced Melanoma: Tebentafusp Treatment Study

We are studying a new treatment for advanced melanoma in patients who have already been treated. This trial compares tebentafusp alone and with pembrolizumab against standard treatment options to see if it improves survival and quality of life.

Uveal MelanomaMetastatic Malignant MelanomaPreviously Treated Non-Ocular Advanced MelanomaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementOncology

Dermatomyositis and Polymyositis: PF-06823859 Study

We are testing a new medication to see if it helps reduce muscle and skin symptoms in adults with active dermatomyositis or polymyositis. This study compares the new treatment to a placebo to evaluate its effectiveness.

Polymyositis and DermatomyositisConfirmation phase (III)Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineRheumatology

Endometrial Cancer: Durvalumab with Chemotherapy

We are studying a new treatment combining durvalumab with standard chemotherapy for patients with advanced or recurrent endometrial cancer. The goal is to see if this approach improves survival and quality of life compared to chemotherapy alone.

Endometrial Cancer>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteGynecology and ObstetricsOncology

Stage III Lung Cancer: MK-7684A Treatment Study

We are studying a new treatment combining MK-7684A with radiation and chemotherapy for patients with unresectable Stage III lung cancer. This trial compares it to standard treatment followed by Durvalumab.

Non-small cell lung cancer≤3 monthsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementInternal MedicineOncology

Cancer Study: LY3537982 for KRAS G12C Mutant Tumors

We are testing a new drug, LY3537982, in patients with advanced solid tumors that have a specific genetic mutation. The goal is to see how well it works and how safe it is when used alone or with other cancer treatments.

KRAS G12C-Mutant Advanced Solid TumorsSafety phase (I)Efficacy phase (II)≤5 visits Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Idiopathic Inflammatory Myopathy: Efgartigimod Treatment

We are studying the long-term safety and effects of a new injection for adults with active idiopathic inflammatory myopathy. This research aims to see if it can help reduce steroid use and improve health outcomes.

Active Idiopathic Inflammatory Myopathy>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementInternal MedicineRheumatology

Wilson Disease: UX701 Gene Therapy Study

We are evaluating a new gene therapy for adults with Wilson disease to see if it safely helps manage copper levels in the body. The study will also look at how it affects the need for current medications and overall liver health.

Wilson's Disease1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementHepatologyInfectious DiseasesInternal Medicine

Propionic Acidemia: mRNA-3927 Treatment Study

We are investigating the safety and effectiveness of mRNA-3927 in individuals with propionic acidemia. The study aims to see if this treatment can reduce serious health events related to the condition.

Propionic AcidemiaSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational MedicinesEndocrinologyInternal Medicine

Partial Lipodystrophy: Metreleptin Treatment Study

We are studying the daily use of metreleptin in patients with partial lipodystrophy to see if it improves their condition and related health factors. This includes looking at liver health and insulin sensitivity over time.

Partial Lipodystrophy>2 yearsMonitoring phase (IV)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteEndocrinologyInternal Medicine

Lung Cancer Treatment: DZD9008 vs. Chemotherapy

We are studying a new medication, DZD9008, for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if it works better than standard chemotherapy.

Advanced Non-Small Cell Lung Cancer with EGFR MutationConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementOncologyPulmonology

Atypical Hemolytic Uremic Syndrome: Long-Term Study of Iptacopan

We are evaluating the long-term safety and effects of iptacopan in individuals with atypical hemolytic uremic syndrome. This study looks at how well the treatment works in preventing complications and improving kidney health.

Atypical Hemolytic Uremic Syndrome>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteNephrology

Advanced Breast Cancer: Giredestrant vs. Fulvestrant

We are studying a new medication, giredestrant, to see if it works better than fulvestrant for patients with advanced breast cancer who have not responded to prior hormone therapy. The trial will also evaluate the safety of both treatments.

Estrogen Receptor Positive, HER2 Negative Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncology

Vericiguat for Vasospastic Angina

We are studying how vericiguat affects heart function and angina episodes in patients with vasospastic angina. The trial also looks at quality of life and safety of the treatment.

Vasospastic Angina1-2 yearsEfficacy phase (II)≤5 visits Post-Trial Drug Access Standard Medicines Partially RemoteCardiologyInternal Medicine

TAK-330 for Reversing Blood Thinner Effects in Urgent Surgery

We are studying whether TAK-330 can effectively reverse the effects of certain blood thinners in patients needing urgent surgery. This trial compares TAK-330 to the standard treatment to see which works better.

Patients on Factor Xa Inhibitors Needing Urgent Intervention≤3 monthsConfirmation phase (III)≤5 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematologyInternal Medicine

Colitis from Cancer Treatment: The iCaD Study

We are comparing a new treatment combining infliximab with corticosteroids for severe colitis caused by immune checkpoint inhibitors. This study aims to see if this combination is more effective than corticosteroids alone.

Immune Checkpoint Inhibitor Related Colitis≤3 monthsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard MedicinesGastroenterologyOncology

Gastrointestinal Stromal Tumors: Imatinib and Atezolizumab Study

We are investigating whether combining imatinib with atezolizumab helps patients with advanced GIST who have not responded to other treatments. The study aims to assess survival rates and quality of life improvements.

Unresectable Gastrointestinal Stromal Tumor (GIST)Metastatic Gastrointestinal Stromal TumorLocally Advanced Gastrointestinal Stromal Tumor (GIST)>2 yearsEfficacy phase (II)Post-Trial Drug Access No Placebo Standard MedicinesOncology

Cystic Fibrosis: Vanzacaftor/Tezacaftor/Deutivacaftor Therapy

We are studying a new combination therapy for cystic fibrosis in individuals aged one year and older. The trial aims to evaluate its long-term safety and effectiveness.

Cystic Fibrosis>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementInternal MedicinePulmonology

Search Clinical Trials in the European Union